Evaluation of LL-37 antimicrobial peptide derivatives alone and in combination with vancomycin against S. aureus

Area of Science:

• Microbiology
• Infectious Diseases
• Biochemistry

Background:

• Antimicrobial resistance in Staphylococcus aureus, including MRSA and VRSA, poses a significant clinical challenge.
• Endogenous antimicrobial peptides (AMPs) represent a potential therapeutic avenue, but their clinical application is often limited.
• The antimicrobial peptide LL-37 and its derivatives are being investigated for their activity against resistant bacterial strains.

Purpose of the Study:

• To evaluate the in vitro activity of the antimicrobial peptide LL-37 and its truncated derivatives, LL-13 and LL-17.
• To assess the synergistic effects of LL-13 and LL-17 in combination with vancomycin against drug-resistant Staphylococcus aureus strains.
• To determine the efficacy of LL-13 and LL-17 in inhibiting Staphylococcus aureus biofilm formation.

Main Methods:

• In vitro susceptibility testing of Staphylococcus aureus strains (including MRSA and VRSA) against LL-37, LL-13, LL-17, and vancomycin.
• Checkerboard assays to evaluate synergistic activity between peptides and vancomycin.
• Biofilm inhibition assays to assess the anti-biofilm properties of the peptides.

Main Results:

• LL-13 and LL-17 demonstrated synergistic activity with vancomycin against vancomycin-resistant S. aureus (VRSA).
• Pretreatment with LL-13 and LL-17 restored vancomycin sensitivity in VRSA strains.
• Both LL-13 and LL-17 exhibited potent inhibition of Staphylococcus aureus biofilm production in vitro.

Conclusions:

• LL-37 derivatives, specifically LL-13 and LL-17, show potential as adjunct therapies for vancomycin-resistant Staphylococcus aureus infections.
• These peptides may be valuable in treating infections where biofilm formation is a contributing factor.
• Further research into LL-37 derivatives could lead to novel strategies against challenging S. aureus infections.